Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 85,589,096
  • Shares Outstanding, K 1,103,950
  • Annual Sales, $ 19,959 M
  • Annual Income, $ 2,408 M
  • 36-Month Beta 0.25
  • Price/Sales 4.11
  • Price/Book 5.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.68 +5.65%
on 12/22/16
78.12 -1.70%
on 01/13/17
+3.41 (+4.65%)
since 12/20/16
3-Month
64.18 +19.65%
on 11/23/16
79.70 -3.65%
on 11/10/16
-1.95 (-2.48%)
since 10/20/16
52-Week
64.18 +19.65%
on 11/23/16
83.78 -8.34%
on 08/01/16
-5.83 (-7.06%)
since 01/20/16

Most Recent Stories

More News
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

North America Insulin Delivery Market Outlook to 2022 - Key Players are Medtronic, Becton Dickinson and Co, Eli Lilly and Company, Insulet & Novo Nordisk - Research and Markets

Research and Markets has announced the addition of the "North America Insulin Delivery Market Outlook to 2022" report to their offering.

InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media

SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed...

InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media

SEATTLE, WA--(Marketwired - Jan 19, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed...

Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?

Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.

Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio

LONDON, UK / ACCESSWIRE / January 19, 2017 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) as both companies announced...

COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 77.93
1st Resistance Point 77.39
Last Price 76.79
1st Support Level 76.53
2nd Support Level 76.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.